Biotechnology Genzyme, the biotech subsidiary of French drug major Sanofi, said this morning that, following “constructive discussions” with the US Food and Drug Administration, the company plans to resubmit in the second quarter its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. 7 April 2014